999 ARVO	First (page Author (required) (Must be author listed first not the Price that another abstract)	For Othce Use Only
BSTRACT	Paid 1999ARVO Member: «Complete Section III)	
' /o - \	Applying for 1999 Membership (must pay by November 16) (Complete Section 11)	
ORM 67 7 1999 5	If mailing takel is not used, enter the First Author's Meinhership Number 2 8	3 5 0 6
	IMPORTANT: Send change of address to membraryolaryolorg	
Scientific Section frequired D	RONG-FANG WANG, MD OPHTHALMOLOGY	
from page 6 which most closely identifies with research submitted.	TOTAL SCHOOL OF MEDICINE 1 GUSTAVE L LEVY PL \$ 1183 NEW YORK NY 10029-6504 rong-f	ang.wang@smtplink.masm.e
	i	
Presentation Preference [required] Check one (1). (B) Paper #1, Poster #2	PATITUTION	
(C) Poster Only (D) Poster #1, Paper #2	STREET ADDRESS	
4 Topic Code List A (required)	CITYSTATE PROVINCE PREFECTURE COUNTRY	ZIP + UNITERNATIONAL POSTA
Enter up to three (3) codes from List A in order of importance starting with the most important.	212 241-5439 (212) 289-5945 OFFICE TELEPHONE NO.* * (required) (Include Intermational Dialing Codes, if applicable) FAX NO. (Important)*	(718) 291-7726 HOME TELEPHONE NO.*
Refer to page 14. 1 8 3 2 1 0 TOPIC A (1) TOPIC A (2)		
TOPIC A (3)	EEFECT OF LATANOPROST (L) OR 8-iso PRO	STAGLANDIN E ₂ (8-
	iso DCEA ALONE AND IN COMBINATION	ON INTRAUCULAR
5 Topic Code List B (required) Enter one (1) code from List B	PRESSURE (IOP) IN GLAUCOMATOUS (G) M	entosa)) Denartment of
that clearly defines your work or enter code for None. Refer to page 15.	Wang, S.M. Podos, J. B. Serle, Thom Mittag, F. Ventosa)) Department of Ophthalmology, The Mount Sinai School of Medicine, New York, NY.	
5 3 9 TOPIC 8	Purpose Raiso PGF2 or Lareduces IOP in both not	rmal and glaucomatous
The state of the s	monkey eyes. The mechanism by which 8-iso PGE	ditivity of the effects of
Travel Fellowship Grant [if applicable]	different from L. This study evaluates the possible ad L and 8-iso PGE ₂ on IOP in G monkey eyes. Metho	ds. IOP was measured

Fellowship Grant? See eligibility

ance with the copyright transfer

provisions and the Animal or Human Subjects Certification

Signature of First (Presenting) Author [required]

Abstract Forms must be received in the ARVO Central Office

by 5:00 PM, EST, Friday.

December 4, 1998.

ARVO Central Office 9650 Rockville Pike Bethesda, MD 20814-3998

and Form on pages 16–18.

7 The Signature of the First

found on page 4 and in Appendix A.

 \mathbf{X} Romat

(Presenting) Author [required] Certifies full compli-

hourly for 6 hrs beginning at 9:30 a.m. on day 1 (baseline day), days 6 and 7 (single agent therapy), and days 13 and 14 (combination therapy with both agents). Following one day of baseline measurement, 4 monkeys with unilateral glaucoma received bid monotherapy with one drop of 0.005% L or 25µl of 0.1% 8-iso PGE2 at 9:30 a.m. and 3:30 p.m. from days 2 to 7. From days 8 to 14 both agents were applied bid 5 min apart. Results. maximum reduction (p<0.05) of IOP was 8.8 ± 1.9 (mean \pm SEM) mmHg (26%) with L alone, and was 6.5 ± 1.0 mmHg (21%) with 8-iso PGE₂ alone 2 hrs after morning dosing on day 7. A further reduction (p<0.05) of IOP of 4.0 ± 0.6 mmHg was produced when 8-iso PGE₂ was added to L, and of $3.0 \pm$ 0.7 mmHg when L was added to 8-iso PGE2 on day 13 before morning Combination therapy with both agents caused maximum IOP reductions (p<0.05) from baseline of 11.3 \pm 3.0 mmHg (33%) (L + 8-iso PGE_2), and 9.8 ± 1.3 mmHg (31%) (8-iso PGE_2 + L). Conclusion. Latanoprost and 8-iso PGE2 have an additive effect on IOP in glaucomatous monkey eyes. Support: NIH grant EY 01867 and unrestricted grant from RPB. CR: P. Cc1, Cc2.